Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

LSTA

Lisata Therapeutics Inc

Nov 21 • 04:00PM ET

1.96

-0.03 -1.51 %

Healthcare • Biotechnology • USA • NASD

Peers: GERN BCLI ALLO BEAM CRSP EDIT FATE NTLA RGNX SRPT

| Held by: VTI VXF DFUS DFAS DFAC DFSU DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	17.10%	Shs Outstand	8.76M	Perf Week	-7.55%
Market Cap	17.29M	Forward P/E	-	EPS next Y	-1.02	Insider Trans	0.00%	Shs Float	7.31M	Perf Month	-16.60%
Enterprise Value	-1.96M	PEG	-	EPS next Q	-0.62	Inst Own	8.54%	Short Float	0.26%	Perf Quarter	-22.53%
Income	-18.24M	P/S	16.16	EPS this Y	7.22%	Inst Trans	-0.98%	Short Ratio	0.29	Perf Half Y	-27.41%
Sales	1.07M	P/B	0.99	EPS next Y	53.97%	ROA	-60.85%	Short Interest	0.02M	Perf YTD	-34.23%
Book/sh	1.98	P/C	0.91	EPS next 5Y	27.62%	ROE	-71.45%	52W High	4.20 -53.33%	Perf Year	-28.73%
Cash/sh	2.15	P/FCF	-	EPS past 3/5Y	31.45% 38.88%	ROIC	-105.00%	52W Low	1.87 4.81%	Perf 3Y	-53.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	83.93%	Volatility	9.68% 10.24%	Perf 5Y	-91.40%
Dividend TTM	-	EV/Sales	-1.83	EPS Y/Y TTM	15.32%	Oper. Margin	-1876.45%	ATR (14)	0.20	Perf 10Y	-98.86%
Dividend Ex-Date	-	Quick Ratio	4.72	Sales Y/Y TTM	-	Profit Margin	-1704.86%	RSI (14)	33.53	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.72	EPS Q/Q	17.92%	SMA20	-15.26%	Beta	1.17	Target Price	13.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-17.34%	Rel Volume	0.42	Prev Close	1.99
Employees	26	LT Debt/Eq	0.00	Earnings	Nov 06 AMC	SMA200	-19.37%	Avg Volume	66.96K	Price	1.96
IPO	Nov 03, 1995	Option/Short	No / Yes	EPS/Sales Surpr.	8.41% -	Trades		Volume	28,225	Change	-1.51%

Nov-07-25 12:00AM	Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... (GuruFocus.com) -12.34%
Nov-06-25 04:05PM	Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' (GlobeNewswire)
Nov-04-25 04:00PM	Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent (GlobeNewswire) -7.49% -5.26%
Oct-30-25 08:00AM	Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 (GlobeNewswire)
08:00AM	Loading…
Oct-13-25 08:00AM	Lisata Therapeutics to Present at LD Micro Main Event XIX (Newsfile)
Oct-09-25 11:16AM	Lisata Therapeutics Partners with Catalent on ADC Technology (Exec Edge)
Oct-08-25 08:30AM	Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement (GlobeNewswire)
Sep-30-25 03:04PM	Lisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer Study (Exec Edge)
Sep-29-25 08:00AM	Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial (GlobeNewswire)
Sep-02-25 08:00AM	Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-07-25 05:33PM	LSTA Applauds Executive Order Increasing 401 (K) Access to Private Markets Investments (Business Wire) -5.41% -7.14%
04:05PM	Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 08:00AM	Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 (GlobeNewswire)
Jul-17-25 02:58PM	Lisata Secures New Composition of Matter Patent for Certepetide (Exec Edge) -6.23%
08:00AM	Loading…
08:00AM	Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update (GlobeNewswire)
Jul-15-25 08:00AM	Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide (GlobeNewswire)
Jun-26-25 08:00AM	Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer (GlobeNewswire) +16.67%
Jun-18-25 05:38AM	Lisata collaborates with GATC Health on drug development (Pharmaceutical Technology)
Jun-17-25 08:00AM	Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development (GlobeNewswire)
Jun-11-25 08:30AM	Lisata Therapeutics to Present at the 2025 BIO International Convention (GlobeNewswire)
May-09-25 03:37AM	Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... (GuruFocus.com) -11.58%
May-08-25 04:05PM	Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 12:40PM	Lisata Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 08:00AM	Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 (GlobeNewswire)
Apr-15-25 08:00AM	Lisata Therapeutics Announces Research License with Catalent (GlobeNewswire) +10.71%
Mar-06-25 08:30AM	Lisata Therapeutics to Present at the Investival Showcase USA (GlobeNewswire)
Mar-05-25 08:30AM	Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development (GlobeNewswire) +10.23%
Feb-28-25 02:35AM	Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... (GuruFocus.com)
Feb-27-25 04:05PM	Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Feb-20-25 08:00AM	Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025 (GlobeNewswire)
Feb-05-25 08:30AM	Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-25 08:00AM	Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -11.64%
Jan-22-25 08:00AM	Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -29.49%
Jan-15-25 08:30AM	Lisata Therapeutics to Present at the 2025 Sequire Investor Summit (GlobeNewswire)
Dec-11-24 10:52AM	Lisata completes subject enrolment in multi-cancer trial of certepetide (Clinical Trials Arena) -6.93%
10:28AM	Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial (Exec Edge)
Dec-10-24 08:30AM	Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial (GlobeNewswire) +6.63%
Dec-04-24 06:28AM	Lisata and Kuva Labs partner for MR imaging agents to detect cancer (Medical Device Network)
Dec-03-24 08:30AM	Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging (GlobeNewswire)
Nov-19-24 08:30AM	Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year' (GlobeNewswire)
Nov-13-24 08:44AM	Q3 2024 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... (GuruFocus.com)
Nov-12-24 04:05PM	Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 09:23AM	Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration (GlobeNewswire)
08:30AM	Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Nov-01-24 12:00PM	Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know (Zacks) +11.66%
Oct-31-24 08:30AM	Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events (GlobeNewswire)
Oct-28-24 08:30AM	Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis (GlobeNewswire)
Oct-03-24 08:00AM	Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events (GlobeNewswire)
Sep-17-24 08:00AM	Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial (GlobeNewswire) +6.53%
Sep-09-24 08:00AM	Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events (GlobeNewswire)
Sep-05-24 08:00AM	Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma (GlobeNewswire) +9.00%
Aug-12-24 04:05PM	Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 08:00AM	Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 (GlobeNewswire) -8.72%
Jul-19-24 06:32AM	Lisata to use Haystacks MRD tests for pancreatic cancer therapy trial (Medical Device Network)
Jul-18-24 11:13AM	Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy (Exec Edge)
08:00AM	Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD Technology to Evaluate Efficacy of Pancreatic Cancer Therapy (GlobeNewswire)
07:30AM	EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy (Benzinga)
Jul-16-24 10:22AM	Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why (Zacks)
08:00AM	Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma (GlobeNewswire)
Jul-10-24 08:00AM	Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model (GlobeNewswire)
Jun-14-24 09:20AM	Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial (Exec Edge)
09:19AM	Lisata Therapeutics CEO encouraged by progress on pancreatic cancer trial (News Direct)
Jun-13-24 08:30AM	Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial (GlobeNewswire)
May-28-24 08:30AM	Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events (GlobeNewswire)
May-20-24 03:58PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)
11:14AM	Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment (MT Newswires)
08:30AM	Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer (GlobeNewswire)
May-13-24 10:45AM	Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results (News Direct) -5.93%
May-10-24 12:39PM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:10PM	Q1 2024 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:47PM	Lisata Therapeutics Net Loss Declines From a Year Earlier (Exec Edge) +5.93%
04:05PM	Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 08:00AM	Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events (GlobeNewswire)
May-02-24 08:00AM	Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-23-24 10:48AM	Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors (News Direct)
09:48AM	Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer (MT Newswires)
07:30AM	Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Apr-10-24 09:53AM	Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma (Zacks)
Apr-09-24 08:30AM	Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma (GlobeNewswire)
Apr-03-24 08:30AM	Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events (GlobeNewswire)
Mar-22-24 12:25PM	Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma (Zacks)
Mar-21-24 08:00AM	Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma (GlobeNewswire) +8.41%
Mar-08-24 08:35AM	Life Science Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-05-24 08:35AM	Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Lisata Therapeutics to Present at the Life Science Investor Forum on March 7 (GlobeNewswire)
Mar-02-24 08:29AM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 08:29AM	Q4 2023 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +5.80%
Feb-29-24 04:05PM	Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.26%
Feb-22-24 08:00AM	Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time (GlobeNewswire)
Feb-20-24 08:00AM	Lisata Therapeutics to Present at BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-24 12:12PM	Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why (Zacks)
Jan-18-24 08:30AM	Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Jan-17-24 08:00AM	Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme (GlobeNewswire)
Jan-04-24 08:00AM	Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy (GlobeNewswire) +7.86%
Dec-12-23 08:00AM	Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +12.60%
Nov-28-23 04:05PM	Lisata Therapeutics to Present at NobleCon19 Investor Conference (GlobeNewswire)
Nov-09-23 04:05PM	Lisata Therapeutics Announces Participation in Upcoming Conferences in November (GlobeNewswire) -5.80%
Nov-07-23 12:00PM	All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy (Zacks)

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

LSTA

Lisata Therapeutics Inc

Upgrade your FINVIZ experience